Metabolism of Ibogaine
Ibogaine is primarily metabolized by the cytochrome P450 enzyme CYP2D6 through O-demethylation to form its main active metabolite noribogaine (12-hydroxyibogamine), which persists in clinically relevant concentrations for days after ibogaine has been cleared 1.
Primary Metabolic Pathway
The predominant metabolic route involves:
- CYP2D6-mediated O-demethylation: This accounts for >95% of total intrinsic clearance at therapeutic concentrations 1
- Primary metabolite: Noribogaine (12-hydroxyibogamine), also called 10-hydroxyibogamine 2
- Bioavailability: Approximately 80% of orally administered ibogaine undergoes O-demethylation to noribogaine 3
Enzyme Kinetics
The O-demethylation exhibits biphasic kinetics suggesting involvement of multiple enzymes 1:
- Low Km activity (Km = 0.55-1.1 μM): Represents the primary pathway, catalyzed by CYP2D6
- High Km activity (Km >200-310 μM): Minor pathway at therapeutic doses, likely involving other P450 isoforms
Critical caveat: CYP2D6 is polymorphically expressed, meaning genetic variations significantly impact ibogaine metabolism 1. Poor metabolizers lacking functional CYP2D6 will have dramatically altered pharmacokinetics, with reduced noribogaine formation and potentially prolonged ibogaine exposure.
Pharmacokinetic Profile
Ibogaine
- Elimination half-life: Rapid clearance from blood 4
- Plasma clearance: Variable based on CYP2D6 phenotype
- First-pass metabolism: Extensive, with majority converted to noribogaine 5
Noribogaine
- Persistence: Remains in clinically relevant concentrations for days to weeks after ibogaine clearance 2, 4
- Clinical significance: The prolonged presence of noribogaine likely accounts for the extended therapeutic effects on craving and mood reported after single-dose administration 4
- Activity: Noribogaine is pharmacologically active and may contribute substantially to both therapeutic and toxic effects 2
Drug-Drug Interaction Risks
Major concern: Co-administration with other CYP2D6 substrates, inhibitors, or inducers can dramatically alter ibogaine and noribogaine concentrations 2:
- CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine): Will increase ibogaine exposure and decrease noribogaine formation
- CYP2D6 inducers: May accelerate ibogaine clearance but increase noribogaine formation
- Competing substrates: Other drugs metabolized by CYP2D6 may compete for metabolism
Clinical implication: Patients taking concurrent medications metabolized by CYP2D6 face unpredictable pharmacokinetics and heightened risk of adverse effects 2.
Additional Metabolic Considerations
Beyond O-demethylation, ibogaine undergoes 3:
- Dealkylation
- Hydroxylation
- Conjugation (likely)
However, these represent minor pathways compared to CYP2D6-mediated metabolism. Essentially all metabolites are eliminated renally 2.
Safety Implications of Metabolism
The metabolic profile has critical safety ramifications:
Cardiotoxicity: Both ibogaine and noribogaine block hERG potassium channels, causing QT prolongation and potentially fatal arrhythmias 2. Noribogaine appears at least as cardiotoxic as the parent compound, meaning cardiac risk persists long after ibogaine administration.
Neurotoxicity: Animal studies show cerebellar neurodegeneration at doses ≥25 mg/kg, though noribogaine may be less neurotoxic than ibogaine 2
Genetic variability: CYP2D6 polymorphisms create unpredictable individual responses, with poor metabolizers at particular risk for altered toxicity profiles 2, 1
Bottom line: The complex, CYP2D6-dependent metabolism of ibogaine, combined with the prolonged presence and activity of noribogaine, creates a pharmacokinetic profile that demands careful consideration of genetic factors, concurrent medications, and extended monitoring periods well beyond initial drug administration.